Nivolumab HS Code Analysis (2026)

Nivolumab is primarily classified under HS code 30021500, which pertains to immunological products, put up in measured doses or in forms or packings for retail sale. The Most Favored Nation (MFN) tariff rates and preferential rates under Free Trade Agreements (FTAs) for this HS code vary across key importing countries:

• Singapore: As a member of the World Trade Organization (WTO), Singapore applies an MFN tariff rate of 0% on pharmaceutical products under HS code 30021500. Additionally, under the India-Singapore Comprehensive Economic Cooperation Agreement (CECA), pharmaceutical products enjoy duty-free access, reinforcing the 0% tariff rate.

• Russia: Russia's MFN tariff rate for HS code 30021500 is 5%. There is no specific FTA between India and Russia that provides preferential tariff rates for pharmaceutical products; thus, the MFN rate applies.

• Brazil: Brazil imposes an MFN tariff rate of 8% on products under HS code 30021500. While Brazil and India are both members of the BRICS group, there is no bilateral FTA between the two countries that offers preferential tariff rates for pharmaceuticals, so the MFN rate remains applicable.

• Seychelles: As a WTO member, Seychelles applies an MFN tariff rate of 0% on pharmaceutical products under HS code 30021500. There is no specific FTA between India and Seychelles affecting this tariff rate.

• Maldives: Maldives maintains an MFN tariff rate of 0% on pharmaceutical products under HS code 30021500. There is no FTA between India and Maldives that alters this rate.

• Japan: Japan's MFN tariff rate for HS code 30021500 is 0%. Under the India-Japan Comprehensive Economic Partnership Agreement (CEPA), pharmaceutical products continue to enjoy duty-free access, maintaining the 0% tariff rate.

• United Kingdom: The UK applies an MFN tariff rate of 0% on pharmaceutical products under HS code 30021500. There is no specific FTA between India and the UK that affects this tariff rate.

• British Virgin Islands: As a British Overseas Territory, the British Virgin Islands follow the UK's tariff schedule, applying an MFN tariff rate of 0% on pharmaceutical products under HS code 30021500.

It's important to note that many countries offer exemptions or reduced tariffs for essential medicines, recognizing their critical role in public health. These exemptions are often outlined in national customs regulations and may apply to products like Nivolumab. Importers should consult the respective national customs authorities or the WTO tariff databases for the most current and detailed information.

Nivolumab is predominantly classified under HS code 30021500, as evidenced by TransData Nexus data indicating that 99.0% of trade value and 148 transactions utilize this code. However, there have been instances where other HS codes have been applied, such as 30049099, 30021400, and 30021290.

The distinction between HS codes 3003 and 3004 is crucial:

• HS 3003: Medicaments (excluding goods of heading 30.02, 30.05, or 30.06) consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale.

• HS 3004: Medicaments (excluding goods of heading 30.02, 30.05, or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses or in forms or packings for retail sale.

Nivolumab, being an immunological product put up in measured doses for retail sale, appropriately falls under HS code 30021500, a subheading of HS 3004.

Common misclassification errors include:

• Classifying Nivolumab under HS 3003: This misstep occurs when the product is incorrectly deemed not to be in measured doses or retail packaging.

• Using HS 30049099: This code is a residual category for other medicaments and may be applied when the specific classification is unclear.

Misclassification can lead to customs penalties, delays in clearance, and potential legal issues. Recent rulings by the World Customs Organization (WCO) and national customs authorities have emphasized the importance of accurate classification, particularly for pharmaceutical products. Importers and exporters should ensure that Nivolumab is correctly classified under HS code 30021500 to avoid such risks.

As of March 26, 2026, Nivolumab does not have specific monographs in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP). In the absence of official monographs, manufacturers and quality control laboratories refer to general chapters and guidelines provided by these pharmacopoeias to establish quality standards.

Key quality parameters for Nivolumab include:

• Purity/Assay Requirements: Ensuring the active pharmaceutical ingredient (API) meets high purity standards, typically ≥99.0%, with stringent controls on impurities.

• Dissolution Testing: While primarily applicable to solid oral dosage forms, dissolution testing may be adapted for injectable formulations to assess the release profile of the drug.

• Stability Testing per ICH Guidelines: Conducting stability studies in accordance with the International Council for Harmonisation (ICH) guidelines, considering different climatic zones to ensure the product maintains its quality over its shelf life.

Manufacturers are advised to develop comprehensive quality control protocols aligned with these general standards and to stay updated with any new monographs or guidelines that may be published in the future.